THERAPEUTIC vaping products manufacturer, From the Fields Pharmaceutical (FTF Pharmaceutical), has announced the appointment of Dr Carolyn Beaumont as its Senior Medical Advisor for smoking cessation.
FTF Pharmaceutical CEO, Wilhelm David, said Dr Beaumont shared a common goal with the therapeutic wellness company, of working towards the major, bipartisan, public health goal of a 5% adult smoking rate in Australia, by the year 2030.
"Dr Beaumont is a well-known, leading local expert in tobacco harm reduction.
"She brings medical expertise and a deep commitment towards reducing the harmful effects of smoking."
Beaumont will become pivotal in promoting and implementing evidence-based strategies within FTF Pharmaceutical, ensuring its Australian standard product portfolio supports patient cessation pathways.
"Striving to drive smoking rates down from double digits to 5% will bring immense benefit," David added.
"Dr Beaumont's appointment reflects our mutual commitment to addressing smoking-related illness and will enable us to better communicate with the medical profession around effective approaches to help enable more Australians to quit."
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Oct 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Oct 23
